甲状腺癌的骨骼并发症与死亡率:一项基于人群的研究
研究基于1991至2011年监测、流行病学和最终结果-医疗保险关联数据库,纳入30063例甲状腺癌患者,分析骨事件(骨转移和骨骼相关事件)的患病率及其对死亡率的影响。结果显示1173例(3.9%)发生骨转移,1661例(5.5%)发生骨骼相关事件;滤泡状和髓样甲状腺癌的骨事件风险高于乳头状甲状腺癌;骨事件与总体和疾病特异性死亡风险升高相关。
要点
- 30063例甲状腺癌患者中,骨转移患病率为3.9%,骨骼相关事件为5.5%。
- 滤泡状和髓样甲状腺癌发生骨转移或骨骼相关事件的概率高于乳头状甲状腺癌。
- 骨事件与总体死亡和疾病特异性死亡风险升高相关,且预后差于其他远处转移。
核心结论
- 甲状腺癌患者的骨事件是不良预后指标。
- 滤泡状和髓样甲状腺癌患者发生骨骼并发症的风险尤其高。
研究设计与样本
- 研究为基于人群的研究,数据来自1991至2011年监测、流行病学和最终结果-医疗保险关联数据库。
- 共纳入30063例甲状腺癌患者。
- 采用多变量逻辑回归识别骨转移和骨骼相关事件的危险因素。
- 采用Cox比例风险回归评估骨事件对死亡率的影响,并校正患者和肿瘤特征。
主要发现
- 30063例患者中,1173例(3.9%)发生骨转移,1661例(5.5%)发生骨骼相关事件。
- 与乳头状甲状腺癌相比,滤泡状甲状腺癌发生骨转移的OR为2.25(95%CI 1.85至2.74),发生骨骼相关事件的OR为1.40(95%CI 1.15至1.68)。
- 与乳头状甲状腺癌相比,髓样甲状腺癌发生骨转移的OR为2.16(95%CI 1.60至2.86),发生骨骼相关事件的OR为1.62(95%CI 1.23至2.11)。
- 骨事件与总体死亡风险升高相关(HR 2.14;95%CI 1.94至2.36),与疾病特异性死亡风险升高相关(HR 1.59;95%CI 1.48至1.71)。
- 与其他远处转移患者相比,骨事件仍是不良预后指标(总体死亡和疾病特异性死亡P均<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Although bone is a common site for tumor metastases, the burden of bone events [bone metastases and skeletal-related events (SREs)] in patients with thyroid cancer is not well known. OBJECTIVE: To measure the prevalence of bone events and their impact on mortality in patients with thyroid cancer. PATIENTS, DESIGN, AND SETTING: We identified patients diagnosed with thyroid cancer between 1991 and 2011 from the linked Surveillance Epidemiology and End Results-Medicare dataset. Multivariable logistic regression was used to identify the risk factors for bone metastases and SREs. We used Cox proportional hazards regressions to assess the impact of these events on mortality, after adjusting for patient and tumor characteristics. RESULTS: Of the 30,063 patients with thyroid cancer, 1173 (3.9%) developed bone metastases and 1661 patients (5.5%) developed an SRE. Compared with papillary thyroid cancer, the likelihood of developing bone metastases or an SRE was higher in follicular thyroid cancer [odds ratio (OR), 2.25; 95% confidence interval (CI), 1.85 to 2.74 and OR, 1.40; 95% CI, 1.15 to 1.68, respectively] and medullary thyroid cancer (OR, 2.16; 95% CI, 1.60 to 2.86 and OR, 1.62; 95% CI, 1.23 to 2.11, respectively). The occurrence of a bone event was associated with greater risk of overall and disease-specific mortality [hazard ratio (HR), 2.14; 95% CI, 1.94 to 2.36 and HR, 1.59; 95% CI, 1.48 to 1.71, respectively]. Bone events were a poor prognostic indicator even when compared with patients with other distant metastases (P < 0.001 and P < 0.001 for overall and disease-specific mortality, respectively). CONCLUSIONS: Bone events in patients with thyroid cancer are a poor prognostic indicator. Patients with follicular and medullary thyroid cancers are at especially high risk for skeletal complications.
引用
- Choksi P, Papaleontiou M, Guo C, et al. Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study. J Clin Endocrinol Metab. 2017. PMID: 28324052. doi:10.1210/jc.2016-3906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。